Authors: Shawver, LK Lipson, KE Fong, TAT McMahon, G Strawn, LM

Citation: Lk. Shawver et al., Receptor tyrosine kinases in angiogenesis, NEW ANGIOTHERAPY, 2002, pp. 409-452

Authors: Strawn, LM Kabbinavar, F Schwartz, DP Mann, E Shawver, LK Slamon, DJ Cherrington, JM

Citation: Lm. Strawn et al., Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts, CLIN CANC R, 6(7), 2000, pp. 2931-2940

Authors: Mendel, DB Schreck, RE West, DC Li, GM Strawn, LM Tanciongco, SS Vasile, S Shawver, LK Cherrington, JM

Citation: Db. Mendel et al., The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function, CLIN CANC R, 6(12), 2000, pp. 4848-4858

Authors: Cherrington, JM Strawn, LM Shawver, LK

Citation: Jm. Cherrington et al., New paradigms for the treatment of cancer: The role of anti-angiogenesis agents, ADV CANC R, 79, 2000, pp. 1-38

Authors: Laird, AD Vajkoczy, P Shawver, LK Thurnher, A Liang, C Mohammadi, M Schlessinger, J Ullrich, A Hubbard, SR Blake, RA Fong, TAT Strawn, LM Sun, L Tang, C Hawtin, R Tang, F Shenoy, N Hirth, KP McMahon, G Cherrington, JM

Citation: Ad. Laird et al., SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors, CANCER RES, 60(15), 2000, pp. 4152-4160